SCHEMBL718539

SCHEMBL718539

Cc1c(C(Nc2ccc(C(=O)O)cc2)C2CCCCC2)oc2ccc([N+](=O)[O-])cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.44
PGR P06401 2/20 0.43
ALDH1A1 P00352 3/20 0.39
RCE1 Q9Y256 1/20 0.39
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 4/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 1/20 0.37
TEAD4 Q15561 1/20 0.37
EPHX1 P07099 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HCAR3 P49019 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720765 0.91 MEN1 (0.41) PGRALDH1A1LMNAHTTKMT2A
SCHEMBL721439 0.85 NPC1 (0.51) ALDH1A1RCE1MAPTNPC1RAB9A
SCHEMBL14905653 0.84 NPC1 (0.49) ALDH1A1RCE1LMNAHTTKMT2A
SCHEMBL720543 0.83 NPC1 (0.52) ALDH1A1RCE1LMNAKMT2AMEN1
SCHEMBL718372 0.83 RCE1 (0.39) ALDH1A1RCE1NPC1RAB9ATEAD4
SCHEMBL716525 0.82 HIF1A (0.38) PGRALDH1A1LMNAHTTKMT2A
SCHEMBL717465 0.79 RCE1 (0.45) ALDH1A1RCE1NPC1RAB9ATEAD4
SCHEMBL719110 0.79 NPC1 (0.41) ALDH1A1RCE1SMN1; SMN2NPC1RAB9A
SCHEMBL717478 0.78 MAPT (0.35) PGRALDH1A1LMNAHTTKMT2A
SCHEMBL716915 0.77 RCE1 (0.45) RCE1NPC1RAB9ATEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PIN1 2485/4885PGR 3412/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PIN1 2485/4885PGR 3412/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.